SAN DIEGO, June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations ...

When gene sequencer giant Illumina (NASDAQ: ILMN) rolled out plans last month to replace the high-performance models of its instruments with a whole new lineup, the market cheered, and the stock rose ...

Article tools E-mail this article Print-friendly version Discuss this articleStocks mentioned in this articleIllumina Inc (ILMN) Stock Quote, Chart, News, Add to WatchlistRelated newsPremarket Movers: ...

Illumina (ILMN) and MyOme announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance ...

Illumina, Inc. (NASDAQ:ILMN) today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, ...

Personal genomics company Helix and Illumina are partnering to support consumer genomics startups. Helix is teaming up with Illumina Accelerator to provide resources and support for innovative ...

Like a child constantly outgrowing clothes, biotech giant Illumina has trouble keeping up with its continued expansion. So on Monday, the San Diego genome sequencing leader is scheduled to open a new ...

Illumina, Inc. ILMN is slated to release fourth-quarter and fiscal 2019 results on Jan 29, after market close. In the last reported quarter, it posted a positive earnings surprise of 37.86%. The ...

Illumina has a profitable business in a large and growing market. Q1 results were strong and since then the stock is up 15%. Q2 should provide more of the same and a good read on key growth drivers.

SAN DIEGO & SANTA CLARA, Calif., Jan 10, 2008 - Affymetrix and Illumina, Inc. (NASDAQ:ILMN) announced today that they have entered into a settlement agreement to resolve their patent litigation. Under ...

Illumina investors got a jolt of encouragement with the announcement of the NovaSeq sequencer line. What can investors expect from here? Illumina follows a typical razor-and-blade business model -- ...

When gene sequencer giant Illumina (NASDAQ: ILMN) rolled out plans last month to replace the high-performance models of its instruments with a whole new lineup, the market cheered, and the stock rose ...